Unknown PHASE4 INTERVENTIONAL 1-arm NCT03725423

Apatinib for Advanced Lung Squmamous Carcinoma

Apatinib Mesylate Was Used in the Treament of Patients With Advanced Lung Squamous Cell Carcinoma of the Third Line and Above

Sponsor: Xuzhou Central Hospital

Conditions Lung Squamous Cell Carcinoma

Interventions Apatinib

Updated 5 times since 2018 Last updated: Oct 30, 2018 Started: Oct 31, 2018 Primary completion: Jun 30, 2019 Completion: Jun 30, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03725423, this PHASE4 trial focuses on Lung Squamous Cell Carcinoma and remains ongoing. Sponsored by Xuzhou Central Hospital, it has been updated 5 times since 2018, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Nov 2020 — Jan 2021 [monthly]

Unknown Status PHASE4

Status: Not Yet Recruiting → Unknown Status
Nov 2018 — Nov 2020 [monthly]

Not Yet Recruiting PHASE4

First recorded

Oct 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Xuzhou Central Hospital

Data source: Xuzhou Central Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.